Neurologic symptoms in Wilson disease (WD) appear at an older age compared to hepatic symptoms and manifest in patients with misdiagnosed liver disease, in patients when the hepatic stage is clinically silent, in the case of non-compliance with anti-copper treatment, or with treatment failure. Neurologic symptoms in WD are caused by nervous tissue damage that is primarily a consequence of extrahepatic copper toxicity. Copper levels in brain tissues as well as cerebrospinal fluid (CSF) are diffusely increased by a factor of 10 and its toxicity involves various mechanisms such as mitochondrial toxicity, oxidative stress, cell membrane damage, crosslinking of DNA, and inhibition of enzymes. Excess copper is initially taken-up and buffered by astrocytes and oligodendrocytes but ultimately causes dysfunction of blood-brain-barrier and demyelination. Most severe neuropathologic abnormalities, including tissue rarefaction, reactive astrogliosis, myelin palor, and presence of iron-laden macrophages, are typically present in the putamen while other basal ganglia, thalami, and brainstem are usually less affected. The most common neurologic symptoms of WD are movement disorders including tremor, dystonia, parkinsonism, ataxia and chorea which are associated with dysphagia, dysarthria and drooling. Patients usually manifest with various combinations of these symptoms while purely monosymptomatic presentation is rare. Neurologic symptoms are largely reversible with anti-copper treatment, but a significant number of patients are left with residual impairment. The approach for symptomatic treatment in WD is based on guidelines for management of common movement disorders. The vast majority of WD patients with neurologic symptoms have abnormalities on brain magnetic resonance imaging (MRI). Pathologic MRI changes include T2 hyperintensities in the basal ganglia, thalami and white matter, T2 hypointensities in the basal ganglia, and atrophy. Most importantly, brain damage and neurologic symptoms can be prevented with an early initiation of anti-copper treatment. Introducing population WD screening, e.g., by exome sequencing genetic methods, would allow early treatment and decrease the neurologic burden of WD.

2nd Department of Neurology Institute Psychiatry and Neurology Warsaw Poland

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine Charles University and General University Hospital Prague Czechia

Department of Radiology 1st Faculty of Medicine Charles University and General University Hospital Prague Czechia

Zobrazit více v PubMed

Wilson SAK. Progressive Lenticular Degeneration: A Familial Nervous Disease Associated with Cirrhosis of the Liver. Brain 1912;34:295-507. 10.1093/brain/34.4.295 PubMed DOI

Dziezyc K, Karlinski M, Litwin T, et al. Compliant treatment with anti-copper agents prevents clinically overt Wilson's disease in pre-symptomatic patients. Eur J Neurol 2014;21:332-7. 10.1111/ene.12320 PubMed DOI

Sternlieb I, Scheinberg IH. Prevention of Wilson's disease in asymptomatic patients. N Engl J Med 1968;278:352-9. 10.1056/NEJM196802152780702 PubMed DOI

Przybylkowski A, Gromadzka G, Chabik G, et al. Liver cirrhosis in patients newly diagnosed with neurological phenotype of Wilson's disease. Funct Neurol 2014;29:23-9. PubMed PMC

Ferenci P. Pathophysiology and clinical features of Wilson disease. Metab Brain Dis 2004;19:229-39. 10.1023/B:MEBR.0000043973.10494.85 PubMed DOI

Litwin T, Dusek P, Szafranski T, et al. Psychiatric manifestations in Wilson's disease: possibilities and difficulties for treatment. Ther Adv Psychopharmacol 2018;8:199-211. 10.1177/2045125318759461 PubMed DOI PMC

Davies KM, Hare DJ, Cottam V, et al. Localization of copper and copper transporters in the human brain. Metallomics 2013;5:43-51. 10.1039/C2MT20151H PubMed DOI

Litwin T, Gromadzka G, Szpak GM, et al. Brain metal accumulation in Wilson's disease. J Neurol Sci 2013;329:55-8. 10.1016/j.jns.2013.03.021 PubMed DOI

Weisner B, Hartard C, Dieu C. CSF copper concentration: a new parameter for diagnosis and monitoring therapy of Wilson's disease with cerebral manifestation. J Neurol Sci 1987;79:229-37. 10.1016/0022-510X(87)90275-9 PubMed DOI

Stuerenburg HJ. CSF copper concentrations, blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson's disease. J Neural Transm (Vienna) 2000;107:321-9. 10.1007/s007020050026 PubMed DOI

Sinha S, Taly AB, Prashanth LK, et al. Sequential MRI changes in Wilson's disease with de-coppering therapy: a study of 50 patients. Br J Radiol 2007;80:744-9. 10.1259/bjr/48911350 PubMed DOI

Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine (Baltimore) 1992;71:139-64. 10.1097/00005792-199205000-00004 PubMed DOI

Verity MA, Gambell JK. Studies of copper ion-induced mitochondrial swelling in vitro. Biochem J 1968;108:289-95. 10.1042/bj1080289 PubMed DOI PMC

Scheiber IF, Bruha R, Dusek P. Pathogenesis of Wilson disease. Handb Clin Neurol 2017;142:43-55. 10.1016/B978-0-444-63625-6.00005-7 PubMed DOI

Reddy PV, Rao KV, Norenberg MD. The mitochondrial permeability transition, and oxidative and nitrosative stress in the mechanism of copper toxicity in cultured neurons and astrocytes. Lab Invest 2008;88:816-30. 10.1038/labinvest.2008.49 PubMed DOI

Letelier ME, Lepe AM, Faundez M, et al. Possible mechanisms underlying copper-induced damage in biological membranes leading to cellular toxicity. Chem Biol Interact 2005;151:71-82. 10.1016/j.cbi.2004.12.004 PubMed DOI

Scheiber IF, Dringen R. Copper-treatment increases the cellular GSH content and accelerates GSH export from cultured rat astrocytes. Neurosci Lett 2011;498:42-6. 10.1016/j.neulet.2011.04.058 PubMed DOI

Bertrand E, Lewandowska E, Szpak GM, et al. Neuropathological analysis of pathological forms of astroglia in Wilson's disease. Folia Neuropathol 2001;39:73-9. PubMed

Vogel FS, Evans JW. Morphologic alterations produced by copper in neural tissues with consideration of the role of the metal in the pathogenesis of Wilson's disease. J Exp Med 1961;113:997-1004. 10.1084/jem.113.6.997 PubMed DOI PMC

Sener RN. Diffusion MR imaging changes associated with Wilson disease. AJNR Am J Neuroradiol 2003;24:965-7. PubMed PMC

Jadav R, Saini J, Sinha S, et al. Diffusion tensor imaging (DTI) and its clinical correlates in drug naive Wilson's disease. Metab Brain Dis 2013;28:455-62. 10.1007/s11011-013-9407-1 PubMed DOI

Finlayson MH, Superville B. Distribution of cerebral lesions in acquired hepatocerebral degeneration. Brain 1981;104:79-95. 10.1093/brain/104.1.79 PubMed DOI

Klos KJ, Ahlskog JE, Kumar N, et al. Brain metal concentrations in chronic liver failure patients with pallidal T1 MRI hyperintensity. Neurology 2006;67:1984-9. 10.1212/01.wnl.0000247037.37807.76 PubMed DOI

Poujois A, Mikol J, Woimant F. Wilson disease: brain pathology. Handb Clin Neurol 2017;142:77-89. 10.1016/B978-0-444-63625-6.00008-2 PubMed DOI

Horoupian DS, Sternlieb I, Scheinberg IH. Neuropathological findings in penicillamine-treated patients with Wilson's disease. Clin Neuropathol 1988;7:62-7. PubMed

Dusek P, Bahn E, Litwin T, et al. Brain iron accumulation in Wilson disease: a post mortem 7 Tesla MRI - histopathological study. Neuropathol Appl Neurobiol 2017;43:514-32. 10.1111/nan.12341 PubMed DOI

Richter R. The pallial component in hepato-lenticular degeneration. J Neuropathol Exp Neurol 1948;7:1-18. 10.1097/00005072-194801000-00001 PubMed DOI

Mikol J, Vital C, Wassef M, et al. Extensive cortico-subcortical lesions in Wilson's disease: clinico-pathological study of two cases. Acta Neuropathol 2005;110:451-8. 10.1007/s00401-005-1061-1 PubMed DOI

Meenakshi-Sundaram S, Mahadevan A, Taly AB, et al. Wilson's disease: a clinico-neuropathological autopsy study. J Clin Neurosci 2008;15:409-17. 10.1016/j.jocn.2006.07.017 PubMed DOI

Nishimuta M, Masui K, Yamamoto T, et al. Copper deposition in oligodendroglial cells in an autopsied case of hepatolenticular degeneration. Neuropathology 2018;38:321-8. 10.1111/neup.12456 PubMed DOI

Anzil AP, Herrlinger H, Blinzinger K, et al. Ultrastructure of brain and nerve biopsy tissue in Wilson disease. Arch Neurol 1974;31:94-100. 10.1001/archneur.1974.00490380042004 PubMed DOI

European Association for Study of L. EASL Clinical Practice Guidelines : Wilson's disease. J Hepatol 2012;56:671-85. PubMed

Lorincz MT. Neurologic Wilson's disease. Ann N Y Acad Sci 2010;1184:173-87. 10.1111/j.1749-6632.2009.05109.x PubMed DOI

Czlonkowska A, Litwin T, Chabik G. Wilson disease: neurologic features. Handb Clin Neurol 2017;142:101-19. 10.1016/B978-0-444-63625-6.00010-0 PubMed DOI

Ferenci P, Czlonkowska A, Merle U, et al. Late-onset Wilson's disease. Gastroenterology 2007;132:1294-8. 10.1053/j.gastro.2007.02.057 PubMed DOI

Ala A, Borjigin J, Rochwarger A, et al. Wilson disease in septuagenarian siblings: Raising the bar for diagnosis. Hepatology 2005;41:668-70. 10.1002/hep.20601 PubMed DOI

Hall HC. La dégénérescence hépato-lenticulaire: maladie de Wilson, pseudo-sclérose. Paris: Masson, 1921.

Denny-Brown D. Hepatolenticular Degeneration (Wilson's Disease). Two Different Components. N Engl J Med 1964;270:1149-56. 10.1056/NEJM196405282702203 PubMed DOI

Marsden CD. Wilson's disease. Q J Med 1987;65:959-66. PubMed

Czlonkowska A, Gajda J, Rodo M. Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate. J Neurol 1996;243:269-73. 10.1007/BF00868525 PubMed DOI

Oder W, Prayer L, Grimm G, et al. Wilson's disease: evidence of subgroups derived from clinical findings and brain lesions. Neurology 1993;43:120-4. 10.1212/WNL.43.1_Part_1.120 PubMed DOI

Konovalov NV. Gepato-tserebral'naia distrofiia. Moscow: Medgiz, 1960.

Aggarwal A, Aggarwal N, Nagral A, et al. A novel Global Assessment Scale for Wilson's Disease (GAS for WD). Mov Disord 2009;24:509-18. 10.1002/mds.22231 PubMed DOI

Czlonkowska A, Tarnacka B, Moller JC, et al. Unified Wilson's Disease Rating Scale - a proposal for the neurological scoring of Wilson's disease patients. Neurol Neurochir Pol 2007;41:1-12. PubMed

Czlonkowska A, Litwin T, Dusek P, et al. Wilson disease. Nat Rev Dis Primers 2018;4:21. 10.1038/s41572-018-0018-3 PubMed DOI PMC

Litwin T, Dusek P, Czlonkowska A. Neurological manifestations in Wilson’s disease –possible treatment options for symptoms. Expert Opinion on Orphan Drugs 2016;4:719-28. 10.1080/21678707.2016.1188003 DOI

Litwin T, Dusek P, Czlonkowska A. Symptomatic treatment of neurologic symptoms in Wilson disease. Handb Clin Neurol 2017;142:211-23. 10.1016/B978-0-444-63625-6.00018-5 PubMed DOI

Hedera P. Treatment of Wilson's disease motor complications with deep brain stimulation. Ann N Y Acad Sci 2014;1315:16-23. 10.1111/nyas.12372 PubMed DOI

Prashanth LK, Taly AB, Sinha S, et al. Prognostic factors in patients presenting with severe neurological forms of Wilson's disease. QJM 2005;98:557-63. 10.1093/qjmed/hci095 PubMed DOI

Svetel M, Kozic D, Stefanova E, et al. Dystonia in Wilson's disease. Mov Disord 2001;16:719-23. 10.1002/mds.1118 PubMed DOI

Berry WR, Darley FL, Aronson AE. Dysarthria in Wilson's disease. J Speech Hear Res 1974;17:169-83. 10.1044/jshr.1702.169 PubMed DOI

da Silva-Junior FP, Carrasco AE, da Silva Mendes AM, et al. Swallowing dysfunction in Wilson's disease: a scintigraphic study. Neurogastroenterol Motil 2008;20:285-90. 10.1111/j.1365-2982.2007.01036.x PubMed DOI

Trocello JM, Osmani K, Pernon M, et al. Hypersialorrhea in Wilson's Disease. Dysphagia 2015;30:489-95. 10.1007/s00455-015-9627-0 PubMed DOI

Dziezyc K, Litwin T, Chabik G, et al. Frequencies of initial gait disturbances and falls in 100 Wilson's disease patients. Gait Posture 2015;42:601-3. 10.1016/j.gaitpost.2015.09.005 PubMed DOI

Verma R, Holla VV, Pandey S, et al. Multifocal myoclonus as a heralding manifestation of Wilson disease. J Pediatr Neurosci 2016;11:358-60. 10.4103/1817-1745.199468 PubMed DOI PMC

Barbosa ER, Silveira-Moriyama L, Machado AC, et al. Wilson's disease with myoclonus and white matter lesions. Parkinsonism Relat Disord 2007;13:185-8. 10.1016/j.parkreldis.2006.03.012 PubMed DOI

Henkin RI, Keiser HR, Jafee IA, et al. Decreased taste sensitivity after D-penicillamine reversed by copper administration. Lancet 1967;2:1268-71. 10.1016/S0140-6736(67)90388-1 PubMed DOI

Degirmenci N, Veyseller B, Hanagasi H, et al. Olfactory function and olfactory bulb volume in Wilson's disease. Eur Arch Otorhinolaryngol 2019;276:139-42. 10.1007/s00405-018-5216-9 PubMed DOI

Mueller A, Reuner U, Landis B, et al. Extrapyramidal symptoms in Wilson's disease are associated with olfactory dysfunction. Mov Disord 2006;21:1311-6. 10.1002/mds.20989 PubMed DOI

Jung KH, Ahn TB, Jeon BS. Wilson disease with an initial manifestation of polyneuropathy. Arch Neurol 2005;62:1628-31. 10.1001/archneur.62.10.1628 PubMed DOI

Prashanth LK, Sinha S, Taly AB, et al. Spectrum of epilepsy in Wilson's disease with electroencephalographic, MR imaging and pathological correlates. J Neurol Sci 2010;291:44-51. 10.1016/j.jns.2010.01.007 PubMed DOI

Dening TR, Berrios GE, Walshe JM. Wilson's disease and epilepsy. Brain 1988;111:1139-55. 10.1093/brain/111.5.1139 PubMed DOI

Trindade MC, Bittencourt T, Lorenzi-Filho G, et al. Restless legs syndrome in Wilson's disease: frequency, characteristics, and mimics. Acta Neurol Scand 2017;135:211-8. 10.1111/ane.12585 PubMed DOI

Cochen De Cock V, Girardot-Tinant N, Woimant F, et al. Sleep Abnormalities in Wilson's Disease. Curr Treat Options Neurol 2018;20:46. 10.1007/s11940-018-0531-4 PubMed DOI

Tribl GG, Trindade MC, Bittencourt T, et al. Wilson's disease with and without rapid eye movement sleep behavior disorder compared to healthy matched controls. Sleep Med 2016;17:179-85. 10.1016/j.sleep.2015.09.003 PubMed DOI

Nevsimalova S, Buskova J, Bruha R, et al. Sleep disorders in Wilson's disease. Eur J Neurol 2011;18:184-90. 10.1111/j.1468-1331.2010.03106.x PubMed DOI

Zhong W, Huang Z, Tang X. A study of brain MRI characteristics and clinical features in 76 cases of Wilson's disease. J Clin Neurosci 2019;59:167-74. 10.1016/j.jocn.2018.10.096 PubMed DOI

Litwin T, Gromadzka G, Czlonkowska A, et al. The effect of gender on brain MRI pathology in Wilson's disease. Metab Brain Dis 2013;28:69-75. 10.1007/s11011-013-9378-2 PubMed DOI PMC

van Wassenaer-van Hall HN, van den Heuvel AG, Algra A, et al. Wilson disease: findings at MR imaging and CT of the brain with clinical correlation. Radiology 1996;198:531-6. 10.1148/radiology.198.2.8596862 PubMed DOI

Hitoshi S, Iwata M, Yoshikawa K. Mid-brain pathology of Wilson's disease: MRI analysis of three cases. J Neurol Neurosurg Psychiatry 1991;54:624-6. 10.1136/jnnp.54.7.624 PubMed DOI PMC

Nazer H, Brismar J, al-Kawi MZ, et al. Magnetic resonance imaging of the brain in Wilson's disease. Neuroradiology 1993;35:130-3. 10.1007/BF00593969 PubMed DOI

Aisen AM, Martel W, Gabrielsen TO, et al. Wilson disease of the brain: MR imaging. Radiology 1985;157:137-41. 10.1148/radiology.157.1.4034959 PubMed DOI

Magalhaes AC, Caramelli P, Menezes JR, et al. Wilson's disease: MRI with clinical correlation. Neuroradiology 1994;36:97-100. 10.1007/BF00588068 PubMed DOI

Sener RN. The claustrum on MRI: normal anatomy, and the bright claustrum as a new sign in Wilson's disease. Pediatr Radiol 1993;23:594-6. 10.1007/BF02014975 PubMed DOI

Lawler GA, Pennock JM, Steiner RE, et al. Nuclear magnetic resonance (NMR) imaging in Wilson disease. J Comput Assist Tomogr 1983;7:1-8. 10.1097/00004728-198302000-00001 PubMed DOI

Hegde S, Sinha S, Rao SL, et al. Cognitive profile and structural findings in Wilson's disease: a neuropsychological and MRI-based study. Neurol India 2010;58:708-13. 10.4103/0028-3886.72172 PubMed DOI

Prashanth LK, Sinha S, Taly AB, et al. Do MRI features distinguish Wilson's disease from other early onset extrapyramidal disorders? An analysis of 100 cases. Mov Disord 2010;25:672-8. 10.1002/mds.22689 PubMed DOI

Sinha S, Taly AB, Ravishankar S, et al. Central pontine signal changes in Wilson's disease: distinct MRI morphology and sequential changes with de-coppering therapy. J Neuroimaging 2007;17:286-91. 10.1111/j.1552-6569.2007.00120.x PubMed DOI

King AD, Walshe JM, Kendall BE, et al. Cranial MR imaging in Wilson's disease. AJR Am J Roentgenol 1996;167:1579-84. 10.2214/ajr.167.6.8956601 PubMed DOI

Saatci I, Topcu M, Baltaoglu FF, et al. Cranial MR findings in Wilson's disease. Acta Radiol 1997;38:250-8. 10.1080/02841859709172059 PubMed DOI

Li X, Feng Z, Tang W, et al. Sex Differences in Clinical Characteristics and Brain MRI Change in Patients With Wilson's Disease in a Chinese Population. Front Physiol 2018;9:1429. 10.3389/fphys.2018.01429 PubMed DOI PMC

Starosta-Rubinstein S, Young AB, Kluin K, et al. Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging. Arch Neurol 1987;44:365-70. 10.1001/archneur.1987.00520160007005 PubMed DOI

Ranjan A, Kalita J, Kumar S, et al. A study of MRI changes in Wilson disease and its correlation with clinical features and outcome. Clin Neurol Neurosurg 2015;138:31-6. 10.1016/j.clineuro.2015.07.013 PubMed DOI

Yu XE, Gao S, Yang RM, et al. MR Imaging of the Brain in Neurologic Wilson Disease. AJNR Am J Neuroradiol 2019;40:178-83. 10.3174/ajnr.A5936 PubMed DOI PMC

Kozic DB, Petrovic I, Svetel M, et al. Reversible lesions in the brain parenchyma in Wilson's disease confirmed by magnetic resonance imaging: earlier administration of chelating therapy can reduce the damage to the brain. Neural Regen Res 2014;9:1912-6. 10.4103/1673-5374.145360 PubMed DOI PMC

Kim TJ, Kim IO, Kim WS, et al. MR imaging of the brain in Wilson disease of childhood: findings before and after treatment with clinical correlation. AJNR Am J Neuroradiol 2006;27:1373-8. PubMed PMC

da Costa Mdo D, Spitz M, Bacheschi LA, et al. Wilson's disease: two treatment modalities. Correlations to pretreatment and posttreatment brain MRI. Neuroradiology 2009;51:627-33. 10.1007/s00234-009-0536-5 PubMed DOI

Thuomas KA, Aquilonius SM, Bergstrom K, et al. Magnetic resonance imaging of the brain in Wilson's disease. Neuroradiology 1993;35:134-41. 10.1007/BF00593970 PubMed DOI

Sener RN. Diffusion MRI findings in Wilson's disease. Comput Med Imaging Graph 2003;27:17-21. 10.1016/S0895-6111(02)00047-2 PubMed DOI

Kawamura N, Ohyagi Y, Kawajiri M, et al. Serial diffusion-weighted MRI in a case of Wilson's disease with acute onset hemichorea. J Neurol 2004;251:1413-4. 10.1007/s00415-004-0555-4 PubMed DOI

Litwin T, Karlinski M, Skowronska M, et al. MR image mimicking the "eye of the tiger" sign in Wilson's disease. J Neurol 2014;261:1025-7. 10.1007/s00415-014-7322-y PubMed DOI PMC

Juan CJ, Chen CY, Liu YJ, et al. Acute putaminal necrosis and white matter demyelination in a child with subnormal copper metabolism in Wilson disease: MR imaging and spectroscopic findings. Neuroradiology 2005;47:401-5. 10.1007/s00234-004-1306-z PubMed DOI

Song YK, Li XB, Huang XL, et al. A study of neurite orientation dispersion and density imaging in wilson's disease. J Magn Reson Imaging 2018;48:423-30. 10.1002/jmri.25930 PubMed DOI

Yang J, Li X, Yang R, et al. Susceptibility-Weighted Imaging Manifestations in the Brain of Wilson's Disease Patients. PLoS One 2015;10:e0125100. 10.1371/journal.pone.0125100 PubMed DOI PMC

Fritzsch D, Reiss-Zimmermann M, Trampel R, et al. Seven-tesla magnetic resonance imaging in Wilson disease using quantitative susceptibility mapping for measurement of copper accumulation. Invest Radiol 2014;49:299-306. 10.1097/RLI.0000000000000010 PubMed DOI

Skowronska M, Litwin T, Dziezyc K, et al. Does brain degeneration in Wilson disease involve not only copper but also iron accumulation? Neurol Neurochir Pol 2013;47:542-6. 10.5114/ninp.2013.39071 PubMed DOI

Sudmeyer M, Saleh A, Wojtecki L, et al. Wilson's disease tremor is associated with magnetic resonance imaging lesions in basal ganglia structures. Mov Disord 2006;21:2134-9. 10.1002/mds.21136 PubMed DOI

Brugieres P, Combes C, Ricolfi F, et al. Atypical MR presentation of Wilson disease: a possible consequence of paramagnetic effect of copper? Neuroradiology 1992;34:222-4. 10.1007/BF00596341 PubMed DOI

Mironov A. Decreased signal intensity of the putamen and the caudate nucleus in Wilson disease of the brain. Neuroradiology 1993;35:166. 10.1007/BF00593979 PubMed DOI

Dusek P, Skoloudik D, Maskova J, et al. Brain iron accumulation in Wilson's disease: A longitudinal imaging case study during anticopper treatment using 7.0T MRI and transcranial sonography. J Magn Reson Imaging 2018;47:282-5. 10.1002/jmri.25702 PubMed DOI

Engelbrecht V, Schlaug G, Hefter H, et al. MRI of the brain in Wilson disease: T2 signal loss under therapy. J Comput Assist Tomogr 1995;19:635-8. 10.1097/00004728-199507000-00026 PubMed DOI

Trocello JM, Guichard JP, Leyendecker A, et al. Corpus callosum abnormalities in Wilson's disease. J Neurol Neurosurg Psychiatry 2011;82:1119-21. 10.1136/jnnp.2009.204651 PubMed DOI

Sinha S, Taly AB, Ravishankar S, et al. Wilson's disease: cranial MRI observations and clinical correlation. Neuroradiology 2006;48:613-21. 10.1007/s00234-006-0101-4 PubMed DOI

van Wassenaer-van Hall HN, van den Heuvel AG, Jansen GH, et al. Cranial MR in Wilson disease: abnormal white matter in extrapyramidal and pyramidal tracts. AJNR Am J Neuroradiol 1995;16:2021-7. PubMed PMC

Das M, Misra UK, Kalita J. A study of clinical, MRI and multimodality evoked potentials in neurologic Wilson disease. Eur J Neurol 2007;14:498-504. 10.1111/j.1468-1331.2006.01676.x PubMed DOI

Yousaf M, Kumar M, Ramakrishnaiah R, et al. Atypical MRI features involving the brain in Wilson's disease. Radiol Case Rep 2015;4:312. 10.2484/rcr.v4i3.312 PubMed DOI PMC

Martinez-Fernandez R, Caballol N, Gomez-Choco M. MRI and transcranial sonography findings in Wilson's disease. Mov Disord 2013;28:740. 10.1002/mds.25492 PubMed DOI

van Wassenaer-van Hall HN. Neuroimaging in Wilson disease. Metab Brain Dis 1997;12:1-19. 10.1007/BF02676350 PubMed DOI

Favrole P, Chabriat H, Guichard JP, et al. Clinical correlates of cerebral water diffusion in Wilson disease. Neurology 2006;66:384-9. 10.1212/01.wnl.0000196482.71636.7d PubMed DOI

Wang A, Wu H, Xu C, et al. Study on Lesion Assessment of Cerebello-Thalamo-Cortical Network in Wilson's Disease with Diffusion Tensor Imaging. Neural Plast 2017;2017:7323121. 10.1155/2017/7323121 PubMed DOI PMC

Li G, Zhou X, Xu P, et al. Microstructure assessment of the thalamus in Wilson's disease using diffusion tensor imaging. Clin Radiol 2014;69:294-8. 10.1016/j.crad.2013.10.016 PubMed DOI

Lawrence A, Saini J, Sinha S, et al. Improvement of Diffusion Tensor Imaging (DTI) Parameters with Decoppering Treatment in Wilson's Disease. JIMD Rep 2016;25:31-7. 10.1007/8904_2015_466 PubMed DOI PMC

Chung EJ, Kim EG, Kim SJ, et al. Wilson's disease with cognitive impairment and without extrapyramidal signs: improvement of neuropsychological performance and reduction of MRI abnormalities with trientine treatment. Neurocase 2016;22:40-4. 10.1080/13554794.2015.1032977 PubMed DOI

Zhou XX, Li XH, Chen DB, et al. The asymmetry of neural symptoms in Wilson's disease patients detecting by diffusion tensor imaging, resting-state functional MRI, and susceptibility-weighted imaging. Brain Behav 2018;8:e00930. 10.1002/brb3.930 PubMed DOI PMC

Trocello JM, Woimant F, El Balkhi S, et al. Extensive striatal, cortical, and white matter brain MRI abnormalities in Wilson disease. Neurology 2013;81:1557. 10.1212/WNL.0b013e3182a95883 PubMed DOI

Roh JK, Lee TG, Wie BA, et al. Initial and follow-up brain MRI findings and correlation with the clinical course in Wilson's disease. Neurology 1994;44:1064-8. 10.1212/WNL.44.6.1064 PubMed DOI

Frota NA, Barbosa ER, Porto CS, et al. Cognitive impairment and magnetic resonance imaging correlations in Wilson's disease. Acta Neurol Scand 2013;127:391-8. 10.1111/ane.12037 PubMed DOI

Semnic R, Svetel M, Dragasevic N, et al. Magnetic resonance imaging morphometry of the midbrain in patients with Wilson disease. J Comput Assist Tomogr 2005;29:880-3. 10.1097/01.rct.0000181723.61974.51 PubMed DOI

Strecker K, Schneider JP, Barthel H, et al. Profound midbrain atrophy in patients with Wilson's disease and neurological symptoms? J Neurol 2006;253:1024-9. 10.1007/s00415-006-0151-x PubMed DOI

Kozic D, Svetel M, Petrovic B, et al. MR imaging of the brain in patients with hepatic form of Wilson's disease. Eur J Neurol 2003;10:587-92. 10.1046/j.1468-1331.2003.00661.x PubMed DOI

Mochizuki H, Kamakura K, Masaki T, et al. Atypical MRI features of Wilson's disease: high signal in globus pallidus on T1-weighted images. Neuroradiology 1997;39:171-4. 10.1007/s002340050386 PubMed DOI

Tribl GG, Trindade MC, Almeida KJ, et al. Quantitative transcranial sonography in Wilson's disease and healthy controls: Cut-off values and functional correlates. J Neurol Sci 2018;385:69-74. 10.1016/j.jns.2017.11.026 PubMed DOI

Maskova J, Skoloudik D, Burgetova A, et al. Comparison of transcranial sonography-magnetic resonance fusion imaging in Wilson's and early-onset Parkinson's diseases. Parkinsonism Relat Disord 2016;28:87-93. 10.1016/j.parkreldis.2016.04.031 PubMed DOI

Svetel M, Mijajlovic M, Tomic A, et al. Transcranial sonography in Wilson's disease. Parkinsonism Relat Disord 2012;18:234-8. 10.1016/j.parkreldis.2011.10.007 PubMed DOI

Walter U, Krolikowski K, Tarnacka B, et al. Sonographic detection of basal ganglia lesions in asymptomatic and symptomatic Wilson disease. Neurology 2005;64:1726-32. 10.1212/01.WNL.0000161847.46465.B9 PubMed DOI

Oertel WH, Tatsch K, Schwarz J, et al. Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease. Ann Neurol 1992;32:743-8. 10.1002/ana.410320607 PubMed DOI

Jeon B, Kim JM, Jeong JM, et al. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease. J Neurol Neurosurg Psychiatry 1998;65:60-4. 10.1136/jnnp.65.1.60 PubMed DOI PMC

Tatsch K, Schwarz J, Oertel WH, et al. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. Nucl Med Commun 1991;12:699-707. 10.1097/00006231-199108000-00005 PubMed DOI

Schlaug G, Hefter H, Engelbrecht V, et al. Neurological impairment and recovery in Wilson's disease: evidence from PET and MRI. J Neurol Sci 1996;136:129-39. 10.1016/0022-510X(95)00293-B PubMed DOI

Piga M, Murru A, Satta L, et al. Brain MRI and SPECT in the diagnosis of early neurological involvement in Wilson's disease. Eur J Nucl Med Mol Imaging 2008;35:716-24. 10.1007/s00259-007-0681-1 PubMed DOI

Giagheddu M, Tamburini G, Piga M, et al. Comparison of MRI, EEG, EPs and ECD-SPECT in Wilson's disease. Acta Neurol Scand 2001;103:71-81. 10.1034/j.1600-0404.2001.103002071.x PubMed DOI

Ishida S, Doi Y, Yamane K, et al. Resolution of cranial MRI and SPECT abnormalities in a patient with Wilson's disease following oral zinc monotherapy. Intern Med 2012;51:1759-63. 10.2169/internalmedicine.51.7341 PubMed DOI

Cordato DJ, Fulham MJ, Yiannikas C. Pretreatment and posttreatment positron emission tomographic scan imaging in a 20-year-old patient with Wilson's disease. Mov Disord 1998;13:162-6. 10.1002/mds.870130131 PubMed DOI

De Volder A, Sindic CJ, Goffinet AM. Effect of D-penicillamine treatment on brain metabolism in Wilson's disease: a case study. J Neurol Neurosurg Psychiatry 1988;51:947-9. 10.1136/jnnp.51.7.947 PubMed DOI PMC

Czlonkowska A, Litwin T, Dziezyc K, et al. Characteristics of a newly diagnosed Polish cohort of patients with neurological manifestations of Wilson disease evaluated with the Unified Wilson's Disease Rating Scale. BMC Neurol 2018;18:34. 10.1186/s12883-018-1039-y PubMed DOI PMC

Meenakshi-Sundaram S, Taly AB, Kamath V, et al. Autonomic dysfunction in Wilson's disease -- a clinical and electrophysiological study. Clin Auton Res 2002;12:185-9. 10.1007/s10286-002-0038-6 PubMed DOI

Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-70. 10.1002/mds.22340 PubMed DOI

Comella CL, Leurgans S, Wuu J, et al. Rating scales for dystonia: a multicenter assessment. Mov Disord 2003;18:303-12. 10.1002/mds.10377 PubMed DOI

Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord 1996;11:136-42. 10.1002/mds.870110204 PubMed DOI

Fahn S, Tolosa E, Marin C. Clinical rating scale for tremor. In: Jankovic J, Tolosa E, editors. Parkinson’s Disease and Movement Disorders. Baltimore-Munich: Urban & Schwarzenberg; 1988. p. 225-34.

Trouillas P, Takayanagi T, Hallett M, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997;145:205-11. 10.1016/S0022-510X(96)00231-6 PubMed DOI

Leinweber B, Moller JC, Scherag A, et al. Evaluation of the Unified Wilson's Disease Rating Scale (UWDRS) in German patients with treated Wilson's disease. Mov Disord 2008;23:54-62. 10.1002/mds.21761 PubMed DOI

Volpert HM, Pfeiffenberger J, Groner JB, et al. Comparative assessment of clinical rating scales in Wilson's disease. BMC Neurol 2017;17:140. 10.1186/s12883-017-0921-3 PubMed DOI PMC

Poujois A, Trocello JM, Djebrani-Oussedik N, et al. Exchangeable copper: a reflection of the neurological severity in Wilson's disease. Eur J Neurol 2017;24:154-60. 10.1111/ene.13171 PubMed DOI

Litwin T, Dziezyc K, Karlinski M, et al. Early neurological worsening in patients with Wilson's disease. J Neurol Sci 2015;355:162-7. 10.1016/j.jns.2015.06.010 PubMed DOI

Kalita J, Kumar V, Chandra S, et al. Worsening of Wilson disease following penicillamine therapy. Eur Neurol 2014;71:126-31. 10.1159/000355276 PubMed DOI

Hahn SH. Population screening for Wilson's disease. Ann N Y Acad Sci 2014;1315:64-9. 10.1111/nyas.12423 PubMed DOI

Poulsen JB, Lescai F, Grove J, et al. High-Quality Exome Sequencing of Whole-Genome Amplified Neonatal Dried Blood Spot DNA. PLoS One 2016;11:e0153253. 10.1371/journal.pone.0153253 PubMed DOI PMC

Murillo O, Luqui DM, Gazquez C, et al. Long-term metabolic correction of Wilson's disease in a murine model by gene therapy. J Hepatol 2016;64:419-26. 10.1016/j.jhep.2015.09.014 PubMed DOI

Weiss KH, Askari FK, Czlonkowska A, et al. Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study. Lancet Gastroenterol Hepatol 2017;2:869-76. 10.1016/S2468-1253(17)30293-5 PubMed DOI

Stremmel W. Bis-choline Tetrathiomolybdate as Old Drug in a New Design for Wilson's Disease: Good for Brain and Liver? Hepatology 2019;69:901-3. 10.1002/hep.30130 PubMed DOI PMC

Brewer GJ, Askari F, Lorincz MT, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 2006;63:521-7. 10.1001/archneur.63.4.521 PubMed DOI

Hobart JC, Cano SJ, Zajicek JP, et al. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 2007;6:1094-105. 10.1016/S1474-4422(07)70290-9 PubMed DOI

Brain morphometry in hepatic Wilson disease patients

The Role of Micronutrients in Neurological Disorders

Cerebral Iron Deposition in Neurodegeneration